Zealand Pharma: FDA acceptance to proceed into Phase 3 trial
(CercleFinance.com) - Denmark's Zealand Pharma said that the US FDA has accepted to proceed with a Phase 3 trial on glepaglutide for short bowel syndrome.
Zealand expects to initiate the pivotal Phase 3 trial, which will enroll up to 130 patients in the US, EU and Canada in the third quarter of 2018.
The biotech firm also said that sales of Soliqua, a combination of lixisenatide and insulin glargine, which is marketed by Sanofi, reached 9 million euros (around 11 million dollars) in the first quarter.
Soliqua is approved in the United States as a therapy for type 2 diabetes inadequately controlled on basal insulin or lixisenatide alone.
While the products is marketed by Sanofi, Zealand receives 10% of global net sales.
Zealand Pharma said that Suliqua's first-quarter sales, another teatment of type 2 diabetes that is marketed by Sanofi, reached 5.5 million euros (6.7 million dollars) in the first quarter.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Zealand expects to initiate the pivotal Phase 3 trial, which will enroll up to 130 patients in the US, EU and Canada in the third quarter of 2018.
The biotech firm also said that sales of Soliqua, a combination of lixisenatide and insulin glargine, which is marketed by Sanofi, reached 9 million euros (around 11 million dollars) in the first quarter.
Soliqua is approved in the United States as a therapy for type 2 diabetes inadequately controlled on basal insulin or lixisenatide alone.
While the products is marketed by Sanofi, Zealand receives 10% of global net sales.
Zealand Pharma said that Suliqua's first-quarter sales, another teatment of type 2 diabetes that is marketed by Sanofi, reached 5.5 million euros (6.7 million dollars) in the first quarter.
Copyright (c) 2018 CercleFinance.com. All rights reserved.